Back To Top
Wegovy (semaglutide) is one of the many Weight Loss Products we sell at Medsforless. It is an injectable medication designed for weight loss in individuals with a BMI exceeding 30. It’s also prescribed for those with a BMI over 27 who have accompanying weight-related health issues such as high blood pressure, diabetes, heart disease, and elevated cholesterol levels. By mimicking a natural hormone in the gut, Wegovy aids in appetite control and induces a sensation of fullness.
Order within
to receive your order on Thursday November 6, 2025
*Product images are for illustrative purposes only, and you may receive a different licensed alternative.
£159.99 – £796.99Price range: £159.99 through £796.99
Wegovy is a prescription weight loss medication that is primarily in the treatment of obesity.
It contains the active ingredient Semaglutide which helps to reduce appetite, maintain a feeling of fullness in the stomach and reduce cravings.
Wegovy is taken as an injectable medicine once a week and is quick and easy to use.
Buying Wegovy online is now easier than before, you can safely, reliably and easily from Meds for Less and expect delivery to your home address within 24 hours.
Wegovy is a prescription, injectable medication that is used primarily for the treatment of obesity and weight management. It contains the active ingredient Semaglutide, a synthetic product which mimics the natural hormone, Glucagon-like peptide-1 (GLP-1).
In the context of obesity, GLP-1 helps regulate appetite and reduce food intake by acting on appetite centres in the brain. This helps people feel fuller sooner, reduces cravings, helps people eat less and allows for weight loss.
Some diabetes control medications also use the active ingredient Semaglutide for their purposes, however the dose of Semaglutide is higher in Weight loss medications like Wegovy than in diabetes medications, like Ozempic.
Please find the Injectable Wegovy Cost of purchase in the table below according to the dosage and number of injections available.
Wegovy Dose | 1-month supply | 2-month supply | 3-month supply |
0.25 mg | £159.99 | £318.99 | £477.99 |
0.5 mg | £159.99 | £318.99 | £477.99 |
1 mg | £159.99 | £318.99 | £477.99 |
1.7 mg | £223.99 | £445.99 | £668.99 |
2.4 mg | £267.99 | £529.99 | £796.99 |
Wegovy and Saxenda are both injectable weight loss medications, however they differ in their active ingredients, dosing, effectiveness and administration schedules.
Wegovy contains the active ingredient Semaglutide which helps to reduce appetite, promote a feeling of fullness and reduce food intake. Saxenda uses the active ingredient, Liraglutide which also promotes a feeling of fullness and reduces cravings for food, however it has a shorter duration of action compared to Semaglutide.
Due to having a longer dose of action, the maintenance dose of Wegovy only needs to be administered once a week however the shorter acting Liraglutide needs to have its maintenance dose taken once a day.
Wegovy has shown to have a 15-20% effectiveness in weight loss in a year when combined with diet and exercise. Saxenda’s effectiveness averages around 5-10% loss of initial body weight over a year.
Saxenda and Wegovy are approved for use in individuals who have a BMI of 30 kg/m2 (classified obese) or BMI of 27 kg/m2 with a weight related condition (like hypertension or type II diabetes).
In countries including the UK, Saxenda has been approved for the use of adults and adolescents (from 12 and above) with obesity whereas Wegovy is only approved for the use of adults (18 and above).
Both, Saxenda and Wegovy have similar side effect profiles since both medicines have active ingredients which act as GLP-1 mimetics. These side effects tend to include nausea, vomiting, constipation, headache and gut discomfort. The side effects are usually more prominent at the start of treatment or during dose increases.
Wegovy is a prescription injectable medication with an initial dose of 0.25 mg once weekly for the first month. Dose increases occur once every 4 weeks until a maintenance dose of 2.4mg once weekly is reached. A sample dosing timetable is given below:
Weeks 0-4: 0.25mg once weekly
Week 5-8: 0.5 once weekly
Week 9-12: 1mg once weekly
Week 13-16: 1.7mg once weekly
Week 17 onwards: maintenance dose of 2.4mg once weekly
The low initial dose and subsequent gradual increase helps patients tolerate the effects and side effects of the medication. Please speak to your healthcare provider about the appropriate dosing and administration schedule for the Injectable Wegovy pen.
Wegovy comes as injectable pen with a certain fixed supply of doses. The pen can be
injected under the skin (subcutaneously) in areas like the abdomen, thigh and upper arm. Wegovy should be taken on the same day each week but it can be taken anytime of the week, with or without food.
WeGovy can help with other conditions, particularly those related to obesity as the effects of weight management can improve metabolic health and reduce the risk factors for other diseases.
Wegovy’s active ingredient Semaglutide can be used in diabetes treatment as demonstrated by diabetes medications Ozempic and Rybelsus . Semaglutide, in its function as a GLP-1 mimetic, increases insulin sensitivity of the body’s cells and insulin secretion by the pancreas.
This is in addition to the helpful weight loss effects it exerts by decreasing appetite leads to a combination effect that can help regulate and reduce blood sugars and help treat diabetes.
Wegovy can help treat Non-alcoholic Fatty Liver Disease (NAFLD), a condition normally associated with obesity and insulin resistance. Wegovy’s ability to increase insulin sensitivity and cause weight loss can be very helpful in treating NAFLD.
Obesity is a major risk factor for heart disease, and high blood pressure, Wegovy’s weight loss effects can help lower blood pressure, lower cholesterol levels and overall cardiovascular strain.
Wegovy’s weight loss effects can also help reduce the severity and effects of conditions like Obstructive Sleep Apnoea, Joint pain and Osteoarthritis, as well as Polycystic Ovary Syndrome.
Wegovy contains the active ingredient Semaglutide at a dose that is meant for weight loss. It has been proven in clinical trials to help people loose 15-20% of their body weight within 68 weeks (1 + year) when combined with a reduced calorie diet and increase physical activity.
Lifestyle changes alone were shown to only have a 5-10% effect on weight loss. Semaglutide’s effect on reducing appetite and increasing satiety can also make it easier to stick to a reduced calorie diet by helping increase the feeling of fullness in the body.
Wegovy has some contraindications (situations it shouldn’t be used in) and potential drug interactions. 
Contraindications for Wegovy include:
Medications to use with caution due to the potential of drug interaction include:
Wegovy is not recommended to be taken during pregnancy due to the potential risks to the developing fetus. Although very few human studies have been performed on the effects of Semaglutide (Wegovy’s active ingredient) in pregnancy, animal studies have shown that Semaglutide to be harmful to the developing fetus.
Women who are on Wegovy and are thinking of trying to conceive are advised to discontinue Wegovy atleast 2 months before trying to conceive.
Aside from Semaglutide/Wegovy’s potential harmful effects on the womb, intentional weight loss (even through other methods) are not recommended during pregnancy due to the independent effect of weight loss on the developing fetus.
Like most medications, Wegovy has a range of side effects that can vary in intensity and type. The more common side effects are typically less serious however the less common side effects tend to be a bit more severe.
Rarer but more serious side effects include:
If you experience any of the rarer yet more serious side effects of Wegovy, please seek medical attention immediately.
Wegovy is a prescription medicine and is not suitable for everyone. You should not use Wegovy if you:
Always speak to your doctor before starting treatment if any of the above apply to you.
Some medicines can interact with Wegovy and may require dose changes or additional monitoring. Tell your doctor if you take:
Wegovy may not be recommended if you have other long-term health conditions. Inform your doctor if you:
Your doctor will assess whether Wegovy is safe and appropriate for you.
There are some alternatives to Wegovy that can be used for weight loss by affecting appetite and metabolic pathways, these options include:
1. Ozempic
2. Wegovy.
3. Saxenda
4. Mounjaro
5. Orlistat
For finding out about other alternatives to Wegovy, or other methods of weight loss or diabetes control, please speak to your healthcare provider.
Clinical studies show that Wegovy for men and Wegovy for women is equally effective in supporting weight management. The medication works by reducing appetite, making it easier to follow a lower-calorie diet. While hormonal and lifestyle factors may influence weight loss speed, both groups achieve significant results with consistent use. For many, the once-weekly Wegovy injection for weight loss provides a simple way to manage obesity while reducing risks of conditions like diabetes and hypertension.
The once-weekly Wegovy injection pen is a weight loss injection pen (Wegovy) designed for simple at-home use. Inject the Wegovy injection for weight loss subcutaneously in the abdomen, thigh, or upper arm, rotating sites each week. Keep pens refrigerated before first use, then store as advised in the leaflet once opened. Never share pens, and dispose of used needles in a sharps bin. If you miss a dose, take it within the window stated by your prescriber, then resume your usual day. Correct technique ensures each Wegovy shot (a weight loss shot Wegovy) delivers the intended dose and helps you stay on track.
Wegovy is a Wegovy weight loss medication (a GLP-1 weight loss medication injection, Wegovy) that works best with structured follow-up. Record weight, waist measurement, appetite and any side effects weekly. Your clinician may adjust the titration schedule or supportive therapies based on response to this Wegovy weight loss med. Many patients find that semaglutide weight loss Wegovy makes sticking to a reduced-calorie diet easier; pairing it with sleep hygiene and activity targets improves outcomes. If motivation dips, arrange a review rather than stopping suddenly—continuity is key to long-term success with Wegovy medication for weight loss.
If you’re looking for a reliable place to purchase Wegovy in the UK, MedsForLess offers a safe and convenient solution. Wegovy is a prescription weight-loss injection containing semaglutide, designed to help individuals with obesity or weight-related conditions achieve long-term weight management. At MedsForLess, you can easily order Wegovy with a valid prescription and have it delivered directly to your door. Buying Wegovy online from a trusted pharmacy ensures you receive genuine medication with secure and fast shipping across the UK. Take the next step in your weight-loss journey today!
Authored:20/10/2025
Jan Davies
GPhC: 3058401
Pharmacist
MPharm | University of Manchester
No. Wegovy is a prescription-only medicine, so you must complete a medical assessment online or visit a doctor to obtain it legally in the UK.
The cost of Wegovy depends on the dose but usually starts from around £159.99 per pen. Higher doses cost more as treatment progresses.
Each Wegovy pen provides one injection per week and lasts for 4 weeks. After that, a new pen is required to continue treatment.
Yes. Wegovy is licensed for weight loss in adults with obesity (BMI ≥30) or BMI ≥27 with weight-related conditions, even if they do not have diabetes.
Wegovy contains semaglutide, which mimics the GLP-1 hormone. It reduces appetite, helps you feel full for longer, and slows how quickly food leaves the stomach.
Most people start with 0.25 mg once a week for the first month. The dose is then gradually increased to 0.5 mg, 1 mg, 1.7 mg and finally 2.4 mg, depending on tolerance.
The most common side effects include nausea, vomiting, stomach pain, diarrhoea or constipation. These are usually mild and improve as the body adjusts to the medication.
No. Wegovy should not be used if you are pregnant, planning pregnancy or breastfeeding. Treatment should be stopped at least two months before trying to conceive.
Moderate alcohol consumption is usually safe, but it may worsen nausea or affect blood sugar levels. It’s best to drink in moderation and avoid alcohol if you feel unwell.
Yes, before first use Wegovy must be stored in the refrigerator (2–8°C). After opening, it can be kept at room temperature below 30°C for up to 28 days.
Yes, if purchased from a licensed online pharmacy that requires a medical questionnaire and issues a private prescription. Avoid non-regulated websites.
If it has been less than 5 days, take the missed dose as soon as possible. If more than 5 days have passed, skip it and take your next injection on the scheduled day. Do not double the dose.
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |